GIVE MOVE: Genotype-Informed Versus Empiric Management Of VirEmia: An Open-Label Randomised Clinical Trial in Children and Adolescents living with HIV.

The Genotype-Informed Versus Empiric Management Of VirEmia (GIVE MOVE) randomised clinical trial assesses the clinical impact and cost-effectiveness of genotypic resistance testing of HIV to inform clinical management in HIV-positive children and adolescents whose treatment is failing to control the virus. Though routine in high-income countries, this key diagnostic tool is not available in many settings where it is most needed.

GIVE MOVE will assess the influence of genotypic resistance testing on clinical decision making and its impact on the health of children and adolescents with unsuppressed HIV-1 and if clinically relevant, assessing the cost and cost-effectiveness of HIV-1 genotypic resistance testing. The cost and cost-effectiveness analysis, in combination with lessons learned with respect to feasibility, are intended to guide implementation of HIV-1 resistance testing in countries or settings were access is currently limited.